Summary
Available information indicates that about 78 new molecules belonging to the class of angiotensin converting enzyme (ACE) inhibitors are under investigation, and that at least 11 or 12 of the newer ACE inhibitors will be available for clinical use. The newer ACE inhibitors can be classified, according to the zinc ion ligand of ACE, into 3 main chemical classes: sulfhydryl-, carboxyl-and phosphoryl-containing ACE inhibitors
All the newer sulfhydryl-containing ACE inhibitors differ from captopril since they are prodrugs, and among them alacepril and probably moveltipril (altiopril, MC 838) are converted in vivo to captopril. When compared with captopril, they show a slower onset and a longer duration of action, and obviously the same route of elimination. Zofenopril, a prodrug that is converted in vivo to the active diacid, shows a greater potency, a similar peak time and a longer duration of action than captopril and, unlike captopril, partial elimination through the liver
The newer carboxyl-containing ACE inhibitors are prodrugs which are converted in vivo to active diacids. Like enalaprilat, they are excreted via the kidney; the exception is spirapril, which is totally eliminated by the liver. Compared to enalapril, benazepril shows an earlier peak time and a slightly shorter terminal half-life, cilazapril and ramipril have an earlier peak time and even longer terminal half-life, perindopril shows similar peak time and terminal half-life, while delapril, quinapril and spirapril show an earlier peak time and a shorter half-life. The phosphoryl-containing ACE inhibitors belong to a new chemical class. Fosinopril is a prodrug which is converted to the active diacid in vivo, shows a relatively late peak time, a long terminal half-life, and is eliminated partially by the liver. SQ 29852, the only newly developed ACE inhibitor which is not a prodrug, seems to be more effective than captopril, with a much longer lasting effect and elimination through the kidney
When the differences in potency between these drugs are compensated by dosage adjustment, all the newer ACE inhibitors are expected to exert a similar amount of inhibition of circulating ACE, and therefore to inhibit to a similar extent the generation of circulating angiotensin II and the breakdown of bradykinin. Obviously they may differ in timing and the duration of circulating ACE inhibition according to their pharmacokinetic properties. With regard to the possibility that they may stimulate prostaglandin synthesis, it is suggested that this action, which does not seem to be specific to this drug class, plays only a minor role in their antihypertensive action; the hypothesis that the sulfhydryl group exerts an additional stimulating action remains to be proved
Experimental data, however, indicate that ACE inhibitors are able to inhibit tissue ACE, that each drug may differ in the amount and duration of ACE inhibition in different tissues, and that tissue bioavailability seems to be the major determinant of these differential effects. These findings raise the theoretical possibility that newer ACE inhibitors might be designed with preferential affinity to various organs, with different therapeutic profiles
As with the systemic humoral effects, it is expected that all the newer ACE inhibitors will exert similar systemic haemodynamic actions. However, the question of whether the different tissue penetration and/or inhibition of the tissue renin-angiotensin system will differentiate the newer ACE inhibitors in terms of regional haemodynamics remains to be answered
The usefulness of the newer ACE inhibitors in the treatment of hypertension and of congestive heart failure is under clinical investigation. Whether these drugs can offer the same or additional advantages or disadvantages as their parent drugs is still in the future
Similar content being viewed by others
References
Abdel-Haq B, Lucarini AR, Magagna A, Arrighi P, Favilla S, et al. Indomethacin reduces the hypotensive effect of lisinopril, but does not modify its renal hemodynamic effects. Abstract no. F032. International Symposium on ACE Inhibition, London, February 14–17, 1989
Abrams WB, Davies RO, Gomez HJ. Clinical pharmacology of enalapril. Journal of Hypertension 2 (Suppl. 2): 31–36, 1984
Ajayi AA, Elliott HL, Reid JL. The pharmacodynamics and doseresponse relationships of the angiotensin converting enzyme inhibitor, cilazapril, in essential hypertension. British Journal of Clinical Pharmacology 22: 167–175, 1986a
Ajayi AA, Lees KR, Reid JL. Effects of angiotensin converting enzyme inhibitor, perindopril, on autonomic reflexes. European Journal of Clinical Pharmacology 30: 177–182, 1986b
Ajayi AA, Reid JL. Renin-angiotensin modulation of sympathetic reflex function in essential hypertension and in the elderly. International Journal of Clinical Pharmacology Research 8: 327–333, 1988
Anderson R, Duchin K, Cone C. Effects of fosenopril sodium on blood pressure in essential hypertension. Abstract 0212. 11th Scientific Meeting of the International Society of Hypertension, Heidelberg, August 31-September 6, 1986
Aono J, Koga T, Yamazaki T, et al. Antihypertensive action of a novel orally active angiotensin converting enzyme inhibitor altiopril calcium (MC-838) in several hypertensive models of rats: comparison with captopril. Archives Internationales de Pharmacodynamie et de Thérapie 292: 203–222, 1988
Arzilli F, Magagna A, Giovannetti R, Nuccorini A, Salvetti A. Acute dose-response curve of enalapril in renovascular hypertensives. American Journal of Hypertension 1 (Suppl. 3): 75–78, 1988
Asaad MM, Antonaccio MJ. Vascular wall renin in spontaneously hypertensive rats: potential relevance to hypertension maintenance and antihypertensive effect of captopril. Hypertension 4: 487–493, 1982
Asmar RG, Journo HJ, Lacolley PJ, Santoni JP, Billaud E, et al. Treament for one year with perindopril: effect on cardiac mass and arterial compliance in essential hypertension. Journal of Hypertension 6 (Suppl. 3): 33–39, 1988
Aurell M, Delin K, Herlitz H, Ljungman S, Witte PU, et al. Pharmacokinetics and pharmacodynamics of ramipril in renal failure. American Journal of Cardiology 59: 65D–69D, 1987
Ball SG. Converting enzyme inhibitors and the cardiovascular system. Journal of Cardiovascular Pharmacology 9 (Suppl. 3): 15–18, 1987
Ball SG, Robertson JIS. A need for new converting enzyme inhibitors? British Medical Journal 290: 180–181, 1985
Ball SG, Robertson JIS. Clinical phrmacology of ramipril. American Journal of Cardiology 59: 23D–27D, 1987
Bauer B, Lorenz H, Zahlten R. An open multicenter study to assess the long-term efficacy, tolerance, and safety of the oral angiotensin converting enzyme inhibitor ramipril in patients with mild to moderate essential hypertension. Journal of Cardiovascular Pharmacology 13 (Suppl. 3): 70–74, 1989
Baum T, Sybertz EJ, Watkins RW, Ahn HS, Nelson S, et al. Antihypertensive activity of SCH31846, a non-sulfhydryl angiotensin-converting enzyme inhibitor. Journal of Cardiovascular Pharmacology 5: 655–667, 1983
Becker RHA, Scholkens B. Ramipril: review of pharmacology. American Journal of Cardiology 59: 3D–11D, 1987
Beerman B, Gomez H, Till A, Junggren IL. Pharmacokinetics of lisinopril in healthy volunteers. Abstract 130. Acta Pharmacologica et Toxicologica 49 (Suppl. V): 66, 1986
Begg EJ. The pharmacokinetics of ACE inhibitors in patients with renal impairment. International Symposium on ACE Inhibition. Satellite Symposium on ACE inhibition in the 90’s, p. 9, London, February 14, 1989
Benazepril Development Group, Princeton. Double-blind comparison of benazepril, hydrochlorothiazide, their combination and placebo in mild to moderate hypertension. American Journal of Hypertension 1: 13A, 1988
Benetos A, Gavras H, Stewart JM, Vavrek RJ, Hatinoglou S, et al. Vasodepressor role of endogenous bradykinin assessed by a bradykinin antagonist. Hypertension 8: 971–974, 1986
Blumberg AL, Denny SE, Marshall GR, Needleman P. Blood vessel hormone interactions: angiotensin, bradykinin and pros-taglandins. American Journal of Physiology 232: H305–H310, 1977
Brunner HR, Gavras H, Waeber B, et al. Oral angiotensin-converting enzyme inhibitor in long-term treatment of hypertensive patients. Annals of Internal Medicine 90: 19–23, 1979
Brunner HR, Nussberger J, Waeber B. The present molecules of converting enzyme inhibitors. Journal of Cardiovascular Pharmacology 7 (Suppl. 1): 2–11, 1985
Brunner HR, Waeber B, Nussberger J. What we would like to know about the antihypertensive mechanisms of angiotensin converting enzyme inhibitors. Journal of Hypertension 6 (Suppl. 3): 1–5, 1988
Bunning P. Inhibition of angiotensin converting enzyme by 2-[N-[(5)-1-carboxy-3-phenylpropyl]-L-alanyl]-[1S,3S,5S-2-azabicyclo(3.3.0) octane-3-carboxylic acid] (HOE 498 diacid). Arzneimittel-Forschung 34: 1406–1410, 1984
Bussien JP, Fasanella d’Amore T, Perret L, Poerchet M, Nussberger J, et al. Single and repeated dosing of the converting enzyme inhibitor perindopril to normal subjects. Clinical Pharmacology and Therapeutics 39: 554–558, 1986
Campbell DJ. Circulating and tissue angiotensin systems. Journal of Clinical Investigation 79: 1–6, 1987
Chaignon M, Barrou Z, Ayad M, Lucsko M, Aubert P, et al. Effects of perindopril on renal haemodynamics and natriuresis in essential hypertension. Journal of Hypertension 6 (Suppl. 3): 61–64, 1988
Cohen ML, Kurz KD. Angiotensin converting enzyme inhibition in tissues from spontaneously hypertensive rats after treatment with captopril or MK-421. Journal of Pharmacology and Experimental Therapeutics 220: 63–69, 1982
Cohen ML, Kurz KD, Shenck KW. Tissue angiotensin converting enzyme inhibition as an index of disposition of enalapril (MK-421) and metabolite MK-422. Journal of Pharmacology and Experimental Therapeutics 226: 192–196, 1983
Consensus Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure. New England Journal of Medicine 316: 1429–1435, 1987
Cushman DW, Wang FL, Fung WC, Harvey CM, DeForrest JM. Differentiation of angiotensin-converting enzyme (ACE) inhibitors by their selective inhibition of ACE in physiologically important target organs. American Journal of Hypertension 2: 294–306, 1989
Debusmann ER, Pujadas JC, Lahn W, Irmisch R, Jané F. Influence of renal function on the pharmacokinetics of ramipril (HOE498). American Journal of Cardiology 59: 70D–78D, 1987
De Feo P, Bolli GB, Motolese M, et al. Benazepril improves glycaemic control in patients with type 2 diabetes and essential hypertension. Abstract F078. International Symposium on ACE Inhibition, London, February 14–17, 1989
De Forrest JM, Powell JR, Cushman DW, Karanewsky D, Petrillo W. Preclinical pharmacological characteristics of SQ 29,852, the prototype of a novel class of angiotensin I converting enzyme (ACE) inhibitors. 11th Scientifibrillationc Meeting of the International Society of Hypertension, pp. 310, Heidelberg, August 31-September 6, 1986
de Leeuw PW, Birkenhager WH. Short-and long-term effects of ramipril in hypertension. American Journal of Cardiology 59: 79D–82D, 1987
De Lepeleire I, Van Hecken A, Verbesselt R, Kaiser G, Barner A. Interaction between furosemide and the converting enzyme inhibitor benazepril in healthy volunteers. European Journal of Clinical Pharmacology 34: 465–468, 1988
Doering W, Maass L, Irmisch R, Konig E. Pharmacokinetic interaction study with ramipril and digoxin in healthy volunteers. American Journal of Cardiology 59: 60D–64D, 1987
Drummer OH, Kourtis S. Biotransformation studies of Di-acid angiotensin converting enzyme inhibitors. Arzneimittel-For-schung/Drug Research 37: 1225–1228, 1987
Duchin KL, Singhvi SM, Willard DA, Migdalo FEBH, McKinstry DN. Captopril kinetics. Clinical Pharmacology and Therapeutic 31: 452–458, 1982
Dusing R, Hoffmann G, Pietsch R, et al. Effect of converting enzyme inhibitors on vascular generation of prostacyclin: the role of kinins. Abstract F033. International Symposium on ACE Inhibition, London, February 14–17, 1989
Dzau VJ. Significance of the vascular renin-angiotensin pathway. Hypertension 8: 553–559, 1986
Dzau VJ. Circulating versus local renin-angiotensin system in cardiovascular homeostasis. Circulation 77 (Suppl. I): 14–113, 1988
Eckert HG, Badian MJ, Gantz D, Kellner HM, Volz M. Pharmacokinetics and biotransformation of 2-[N-[(S)-l-ethoxycar-bonyl-3-phenylpropyl]-L-alanyl]-(1S,3S,5S)-2-azabicyclo 3.0 octane-3-carboxylic acid (Hoe 498) in rat, dog and man. Arzneimittel-Forschung 34: 1435–1447, 1984
Edwards CRW, Padfibrillationeld PL. Angiotensin-converting enzyme inhibitors: past, present and bright future. Lancet 1: 30–34, 1985
Eichstaedt H, Danne O, Langer M, Cordes M, Schubert C, et al. Regression of left ventricular hypertrophy under ramipril treatment investigated by nuclear magnetic resonance imaging. Journal of Cardiovascular Pharmacology 13 (Suppl. 3): 75–80, 1989
Fasanella d’Amore T, Bussien JP, Nussberger J, Waeber B, Turini GA, et al. Effects of single doses of the converting enzyme inhibitor cilazapril in normal volunteers. Journal of Cardiovascular Pharmacology 9: 26–31, 1987
Faxon DP. ACE inhibition for the failing heart: experience with captopril. American Heart Journal 115: 1085–1093, 1988
Ferry JJ, Cetnarowski AB, Sedman AJ, Thomas RW, Horvath AM. Multiple-dose cimetidine administration does not influence the single-dose pharmacokinetics of quinapril and its active metabolite (CI-928). Journal of Clinical Phrmacology 28: 48–51, 1988
Ferry JJ, Horvath AM, Sedman AJ, Latts JR, Colburn WA. Influence of food on the pharmacokinetics of quinapril and its active diacid metabolite, CI-928. Journal of Clinical Pharmacology 27: 397–399, 1987
Fillastre JP, Moulin B, Godin M, Williams PEO, Brown AN, et al. Pharmacokinetics of cilazapril in patients with renal failure. British Journal of Clinical Pharmacology 27: 2755–2825, 1989
Foult JM, Tavolaro O, Antony I, Nitenberg A. Direct myocardial and coronary effects of enalaprilat in patients with dilated cardiomyopathy: assessment by a bilateral intracoronary infusion technique. Circulation 77: 337–344, 1988
Francis GS. Heart failure management: the impact of drug therapy on survival. American Heart Journal 115: 699–702, 1988
Francis RJ, Brown AN, Kler L, Fasanella d’Amore T, Nussberger L, et al. Pharmacokinetics of the converting enzyme inhibitor cilazapril in normal volunteers and the relationship to enzyme inhibition: development of a mathematical model. Journal of Cardiovascular Pharmacology 9: 32–38, 1987
Francis RJ, Brown AN, Rajaguru S, Steiner J, Curry PVL. A pharmacokinetic study of cilazapril in patients with congestive heart failure. First International Symposium: cilazapril preclinical and clinical pharmacology, p. 16, Lausanne, May 5–7, 1988
Frank GJ, Phelps MC, Quade MM. Quinapril hydrochloride in the treatment of moderate-to-severe hypertension. Abstract F109. International Symposium of ACE Inhibition, London, February 14–17, 1989
Frank GJ, Wolfing A, Lilienthal J. Comparison of two ACE inhibitors, quinapril hydrochloride and enalapril, when given in addition to chlorthalidone in patients with moderate to severe hypertension. Abstract P200. European Heart Journal 9 (Suppl. 1): A33, 1988
Frohlich ED, Cooper RA, Lewis EJ. Review of the overall experience of captopril in hypertension. Archives of Internal Medicine 144: 1441–1444, 1984
Gavras H. The place of angiotensin-converting enzyme inhibition in the treatment of cardiovascular diseases. New England Journal of Medicine 319: 1541–1543, 1988
Gavras I, Vlahakos D, Melby JC, Gavras H. Pilot study of effects of the angiotensin-converting enzyme inhibitor CI-906 on patients with essential hypertension. Journal of Clinical Pharmacology 24: 343–350, 1984
Geyskes GG, Abma G, Frijns TJMA, van Schaik BAM. Effect of a new ACE inhibitor (CGS 14824A): in patients with renal insufficiency. Abstract 0801. 12th Scientifibrillationc Meeting of the International Society of Hypertension, Kyoto, May 22–26, 1988
Given BD, Perentesis GP, Affrime MB. Spirapril (SCH 33844), a long acting ACE inhibitor effective in once daily treatment of hypertension. Abstract F011. International Symposium on ACE Inhibition, London, February 14–17, 1989
Gohlke P, Urbach H, Scholkens B, Unger T. Inhibition of converting enzyme in the cerebrospinal fluid of rats after oral treatment with converting enzyme inhibitors. Journal of Pharmacology and Experimental Therapeutics 249: 609–616, 1989
Heel RC, Brogden RN, Speight TM, Avery GD. Captopril: a preliminary review of its pharmacological properties and therapeutic efficacy. Drugs 20: 409–452, 1980
Hof RP, Hof-Miyashita A, Evenou JP. Hemodynamic effects of a new angiotensin converting enzyme inhibitor, spirapril, in sodium-loaded and sodium-depleted rabbits. Journal of Cardiovascular Pharmacology 10: 599–606, 1987
Holt P, Najm J, Sowton E. The acute haemodynamic effects of quinapril, a new non-sulfhydryl angiotensin converting enzyme inhibitor, in patients with severe congestive cardiac failure. European Journal of Clinical Pharmacology 31: 9–14, 1986
Hosie J, Berghoff W, Frank GJ. Pharmacokinetics of once-daily oral quinapril HC1 in young subjects and elderly hypertensive patients. Abstract F029. International Symposium on ACE Inhibition, London, February 14–17, 1989
Hosie J, Hosie G. The pharmacokinetics of ramipril in elderly hypertensives. Abstract F050. International Symposium on ACE Inhibition, London, February 14–17, 1989
Inada Y, Terashita Z, Imura Y, Tanabe M, Nishikawa K, et al. Inhibition of angiotensin converting enzyme by CV-3317, a non-sulfhydryl compound. Japanese Journal of Pharmacology 42: 99–108, 1986
Jackson B, Cubela R, Johnston CI. Characterization of angiotensin converting enzyme from rat tissue by radioinhibitor binding studies. Clinical and Experimental Pharmacology and Physiology 13: 681–689, 1986
Jackson B, Cubela RB, Sakaguchi K, Johnston CI. Characterization of angiotensin converting enzyrne (ACE) in the testis and assessment of the in vivo effects of the ACE inhibitor perindopril. Endocrinology 122: 50–55, 1988
Jauch KW, Hartl W, Guenther B, Wicklmayr M, Rett K, et al. Captopril enhances insulin responsiveness of forearm muscle tissue in non-insulin-dependent diabetes mellitus. European Journal of Clinical Investigation 17: 448–454, 1987
Johnston CI, Mendelsohn FAO, Cubela RB, Jackson B, Kohzuki M, et al. Inhibition of angiotensin converting enzyme (ACE) in plasma and tissues: studies ex vivo after administration of ACE inhibitors. Journal of Hypertension 6 (Suppl. 3): 17–22, 1988
Karleberg BE, Lindstrom T, Rosenqvist U, Ohman KP. Efficacy, tolerance and hormonal effects of a new oral angiotensin converting enzyme inhibitor, ramipril (HOE 498), in mild to moderate primary hypertension. American Journal of Cardiology 59: 104D–109D, 1987
Koskinen P, Manninen V, Eisalo A. Quinapril and blood lipids. British Journal of Clinical Pharmacology 26: 478–480, 1988
Kostis JB. Angiotensin converting enzyme inhibitors. American Journal of Hypertension 2: 57–64, 1989
Lambert AE, Brichard S, Ketelslegers JM. Renal function, glycaemic control and perindopril in diabetic patients. 1st International Meeting of Hypertension, Renin-Angiotensin System and Perindopril, Paris, October 29, 1988
Lancaster SG, Todd PA. Lisinopril: preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in hypertension and congestive heart failure. Drugs 35: 646–669, 1988
Laubie M, Schiavi P, Vincent MK, Schmitt H. Inhibition of angiotensin I-converting enzyme with S 9490: biochemical effects, interspecies differences, and role of sodium diet in hemodynamic effects. Journal of Cardiovascular Pharmacology 6: 1076–1082, 1984
Lees KR, Hughes DM, McNeill CA, Reid JL. Pharmacokinetics of perindopril: therapeutic consequences. 1st International Meeting of Hypertension, Renin-Angiotensin System and Perindopril, Paris, October 29, 1988
Lees KR, Kelman AW, Meredith P, et al. Pharmacokinetics of the angiotensin converting enzyme inhibitor, perindopril, after repeated oral dosing. British Journal of Clinical Pharmacology 22 (Suppl. 2): 233–234, 1986
Lees KR, Reid JL. The haemodynamic and humoral effects of treatment for one month with the angiotensin converting enzyme inhibitor perindopril in salt replete hypertensive patients. European Journal of Clinical Pharmacology 31: 519–524, 1987a
Lees KR, Reid JL. Haemodynamic and humoral effects of oral perindopril, an angiotensin converting enzyme inhibitor, in man. British Journal of Clinical Pharmacology 23: 159–164, 1987b
Lees KR, Reid JL, Scott MGB, Hosie J, Herpin D, et al. A double blind comparison of perindopril and captopril in mild to moderate essential hypertension. Abstract F075. International Symposium on ACE Inhibition, London, February 14–17, 1989
Leonetti G, Lucchelli PD, Mazzola C, Pasotti C, Stornello M, et al. Comparative study of the efficacy and safety of perindopril and atenolol in essential hypertension. Abstract F046. International Symposium on ACE Inhibition, London, February 14–17, 1989
Lernhardt EB, Ziegler MG. Cilazapril induced cough. Clinical Re-search 35: 377A, 1987
Lindpaintner K, Jin M, Wilhelm MJ, Suzuki F, Linz W, et al. Intracardiac generation of angiotensin and its physiologic role. Circulation 77 (Suppl. I): 118–123, 1988
Linz W, Martorana PA, Grotsch S, Scholkens BA. The cardioprotective effects of the ACE-inhibitor ramipril resemble those of bradykinin in ischemic hearts. Abstract F116. International Symposium on ACE Inhibition, London, February 14–17, 1989
Luccioni R, Frances Y, Gass R, Fressinaud P, Gilgenkrantz JM. Blood pressure profiles and dose-effect relationship of perindopril. 1st International Meeting of Hypertension, Renin-Angiotensin System and Perindopril, Paris, October 29, 1988
MacDonald NJ, Lloyd P, Sioufibrillation A, Elliott HL, Hughes DM, et al. Age and the pharmacodynamics and pharmacokinetics of benazepril. Abstract F141. International Symposium on ACE Inhibition, London, February 14–17, 1989
Mackaness GB. The future of angiotensin-converting enzyme inhibitors. Journal of Cardiovascular Pharmacology 7 (Suppl. 1): S30–S34, 1985
Man in’t Veld AJ, Schicht IM, Derkx FHM, et al. Effects of an angiotensin-converting enzyme inhibitor (captopril) on blood pressure in anephric subjects. British Medical Journal 280: 288–290, 1980
Manning AS, Lad N, Crome R. Reperfusion arrhythmias: beneficial actions of cilazapril. Cardiovascular Drugs and Therapy 1 (Suppl. 3): 264, 1987
Massarella JW, Silvestri TM, Lin A, Brown AN. Pharmacokinetics and dose proportionality of cilazapril. First International Symposium on Cilazapril: Preclinical and Clinical Pharmacology, p. 12, Lausanne, May 5–7, 1988
Matsumoto K, Miyazaki H, Fujii T, et al. Disposition and metabolism of the novel antihypertensive agent alacepril in rats. Arzneimittel/Forschung 36: 40–46, 1986
McGiff JC, Terragno NA, Malik KU, Lonigro AJ. Release of a prostaglandin E-like substance from canine kidney by bradykinin. Circulation Research 31: 36–43, 1972
Meisel S, Verhorn M, Rosenthal T. Ramipril (HOE 498) for the treatment of severe hypertension. Abstract no. F124. International Symposium on ACE Inhibition, London, February 14–17, 1989
Meredith PA, Elliott HL, Reid JL. The pharmacokinetics of single oral doses of cilazapril in patients with moderate essential hypertension. First International Symposium on Cilazapril: Preclinical and Clinical Pharmacology, p. 15, Lausanne, May 5–7, 1988
Meyer BH, Muller FO, Badian M, Eckert HG, Hajdù P, et al. Pharmacokinetics of ramipril in the elderly. American Journal of Cardiology 59: 33D–37D, 1987
Mimran A, Targhetta R, Laroche B. The antihypertensive effect of captopril: evidence for an influence of kinins. Hypertension 2: 732–737, 1980
Mizuno K, Nakamaru M, Higashimori K, Inagami T. Local generation and release of angiotensin II in peripheral vascular tissue. Hypertension 11: 223–229, 1988
Morice AH, Brown MJ, Higenbottam T. Cough association with angiotensin converting enzyme inhibition. Journal of Cardiovascular Pharmacology 13 (Suppl. 3): S59–S62, 1989
Mulrow CD, Mulrow JP, Linn WD, Aguilar C, Ramirez G. Relative efficacy of vasodilator therapy in chronic congestive heart failure. Journal of the American Medical Association 259: 3422–3426, 1988
Natoff IL, Nixon JS, Francis RJ, Klevans LR, Brewster M, et al. Biological properties of the angiotensin converting enzyme inhibitor cilazapril. Journal of Cardiovascular Pharmacology 7: 569–580, 1985
Noguchi K, Kato T, Sunagawa R, et al. Comparison of acute hemodynamic effects of MC-838, a new angiotensin converting enzyme inhibitor, with captopril in anesthetised dogs. Japanese Journal of Pharmacology 40: 373–380, 1986
Nussberger J, Fasanella d’Amore T, Portchet M, Waeber B, Brummer DB, et al. Repeated administration of the converting enzyme inhibitor cilazapril to normal volunteers. Journal of Cardiovascular Pharmacology 9: 39–44, 1987
Ogihara T, Nakamaru M, Higaki J, et al. Effect of CV-3317, an orally active converting enzyme inhibitor, in normal volunteers (phase I study). Japanese Pharmacology and Therapy 11: 4663–4681, 1983
Oka Y, Nishikawa K, Kito G, Mayahara H, Tanayama S, et al. Delapril. Cardiovascular Drug Reviews 6: 192–205, 1988
Okamura T, Miyazaki M, Inagami T, Toda N. Vascular renin angiotensin system in 2-kidney, 1-clip hypertensive rats. Hypertension 8: 560–565, 1986
Ondetti MA. Structural relationships of angiotensin converting enzyme inhibitors to pharmacological activity. Circulation 77 (Suppl. I): 74–78, 1988
Ondetti MA, Rubin B, Cushman DW. Design of specific inhibitors of angiotensin converting enzyme: a new class of orally active antihypertensive agents. Science 196: 441–446, 1977
Onoyama K, Hirakata H, Tsuruda H, et al. Pharmacokinetics of a new angiotensin I converting enzyme inhibitor (alacepril) after oral dosing in fasting or fed states. Clinical Pharmacology and Therapeutics 38: 462–468, 1985
Onoyama K, Nanishi F, Okuda S, Oh Y, Fujishima M, et al. Pharmacokinetics of a new angiotensin I converting enzyme inhibitor (delapril) in patients with deteriorated kidney function and in normal control subjects. Clinical Pharmacology and Therapeutics 43: 242–249, 1988
Owens GK. Influence of blood pressure on development of aortic medical smooth muscle hypertrophy in spontaneously hypertensive rats. Hypertension 9: 178–187, 1987
Packer M, Hung Lee W, Yushak M, Medina N. Comparison of captopril and enalapril in patients with severe chronic heart failure. New England Journal of Medicine 315: 847–853, 1986
Passmore AP, Kondowe GB, Johnston GD. Effect of cilazapril, a new angiotensin converting enzyme inhibitor, on renal hemodynamics, prostaglandin and electrolyte excretion. Clinical Pharmacology and Therapeutics 43: 198, 1988
Perani G, Marchesi E, Folino P, Muggia C, Martignoni A, et al. Double blind comparison of the effects of perindopril and captopril on plasma lipids and lipoproteins. Abstract F072. International Symposium on ACE Inhibition, London, February 14–17, 1989
Petrillo EW, Powell JR, Cushman DW, Ondetti MA. Angiotensin converting enzyme inhibitors: accomplishments and challenges. Clinical and Experimental Hypertension — Theory and Practice A9: 235–241, 1987
Pfeffer MA, Lamas GA, Vaughan DE, Parisi AF, Braunwald E. Effect of captopril on progressive ventricular dilatation after anterior myocardial infarction. New England Journal of Medicine 319: 80–86, 1988
Plouin PF, Gelas FA, Haldigier JG, Pressinaud P, Dollin C, et al. Effect of perindopril (S-9490) on blood pressure and renin-angiotensin-aldosterone system in hypertensive men. Clinical and Experimental Hypertension A9: 1988, 1987
Predel HG, Dusing R, Backer A, Kipnowski J, Kramer HJ. Combined treatment of severe essential hypertension with the new angiotensin converting enzyme inhibitor ramipril. American Journal of Cardiology 59: 143D–148D, 1987
Re R, Rovigatti U. New approaches to the study of the cellular biology of the cardiovascular system. Circulation 77 (Suppl. I): 1–14, 1988
Reid JL, Kennedy RL, Perret L. Perindopril, a new angiotensin converting enzyme inhibitor: clinical pharmacological studies in healthy subjects. Clinical and Experimental Hypertension — Theory and Practice A9: 361–364, 1987
Ribner H, Glasser S, Sagar K, Larkin S, Whalen J. Initial study of effects of benazepril on exercise tolerance in heart failure patients. Abstract 1851. European Heart Journal 9 (Suppl. 1): 334, 1988
Richer C, Dousseau MP, Giudicelli JF. Systemic and regional hemodynamic profibrillationle of fibrillationve angiotensin I converting enzyme inhibitors in spontaneously hypertensive rats. American Journal of Cardiology 59: 12D–17D, 1987
Richer C, Giroux B, Plouin PF, Maarek B, Giudicelli JF. Captopril: pharmacokinetics, antihypertensive and biological effects in hypertensive patients. British Journal of Clinical Pharmacology 17: 243–250, 1984
Rochette L, Ribout C, Belichard P, Bril A, Devissaguet M. Protective effect of angiotensin converting enzyme inhibitors (CEI): captopril and perindopril on vulnerability to ventricular fibrillationbrillation during myocardial ischemia and reperfusion in rat. Clinical and Experimental Hypertension — Theory and Practice A9: 365–368, 1987
Rotmensch HH, Vlasses PH, Ferguson RK. Angiotensin converting enzyme inhibitors. Medical Clinics of North America 72: 399–424, 1988
Rudd P, Zachary V, Fenster R. Long term safety and efficacy of cilazapril for mild ambulatory hypertension. Abstract F090. International Symposium on ACE Inhibition, London, February 14–17, 1989
Sakaguchi K, Chai SY, Jackson B, Johnston CI, Mendelsohn FAO. Inhibition of tissue angiotensin converting enzyme: quantitation by autoradiography. Hypertension 11: 231–238, 1988
Salvetti A. Angiotensin-converting enzyme inhibitors in the treatment of mild to moderate essential hypertension. American Journal of Hypertension 2: 94S–99S, 1989
Salvetti A, Abdel-Haq B, Magagna A, Pedrinelli R. Indomethacin reduces the antihypertensive action of enalapril. Clinical and Experimental Hypertension — Theory and Practice A9: 559–567, 1987
Salvetti A, Arzilli F. Chronic dose-response curve of enalapril in essential hypertensives: an Italian multicenter study. American Journal of Hypertension 2: 352–354, 1989
Salvetti A, Arzilli F, Pedrinelli R, Beggi P, Motolese M. Interaction between oxprenolol and indomethacin on blood pressure in essential hypertensive patients. European Journal of Clinical Pharmacology 22: 197–201, 1982a
Salvetti A, Pedrinelli R, Alberigi P, Magagna A, Abdel-Haq B. The influence of indomethacin and sulindac on some pharmacological actions of atenolol in hypertensive patients. British Journal of Clinical Pharmacology 17: 108S–111S, 1984
Salvetti A, Pedrinelli R, Arzilli F, Abdel-Haq B, Magagna A, et al. Angiotensin converting enzyme inhibitors in hypertension: a review. International Journal of Clinical and Pharmacological Research 5(6): 429–438, 1985a
Salvetti A, Pedrinelli R, Magagna A, Abdel-Haq B, Graziadei L, et al. Influence of food on acute and chronic effects of captopril in essential hypertensive patients. Journal of Cardiovascular Pharmacology 7 (Suppl. 1): 25–29, 1985b
Salvetti A, Pedrinelli R, Magagna A, Ugenti P. Differential effects of selective and non-selective prostaglandin synthesis inhibition on the pharmacological responses to captopril in patients with essential hypertension. Clinical Science 63: 261S–263S, 1982b
Santoni JP, Richard C, Pouyollon F, Castaings C. Tolerance and safety of perindopril. 1st International Meeting on Hypertension, Renin-Angiotensin System and Perindopril (Coversyl), Paris, October 29, 1988
Sassano P, Pedrinelli R, Magagna A, Abdel-Haq B, Salvetti A. Humoral and hemodynamic effects of increasing doses of captopril in patients with essential hypertension. American Journal of Cardiology 49: 1574–1576, 1982
Sassano P, Serrurier D, Bellet M, Guyenne TT, Corvol P, et al. Advantages of a cross-over design to investigate the dose-dependency of blood pressure and renin release during converting enzyme inhibition by benazepril, in hypertensive patients. Abstract 0031. 12th Scientific Meeting of the International Society of Hypertension, Kyoto, May 22–26, 1988
Saynavalammi P, Porsti I, Nurmi AK, Seppala E, Metsa-ketela T, et al. Inhibition of angiotensin-converting enzyme with quinapril (CI-906): investigation of antihypertensive mechanisms in spontaneously hypertensive rats. Journal of Pharmacology and Experimental Therapeutics 237: 246–249, 1986
Schaller MD, Nussberger J, Waeber B, Bussien JP, Turini GA, et al. Haemodynamic and pharmacological effects of the converting enzyme inhibitor CGS 14824A in normal volunteers. European Journal of Clinical Pharmacology 28: 267–272, 1985
Scholkens BA, Linz W, Konig W. Effects of the converting enzyme inhibitor, ramipril, in isolated ischemic rat heart are abolished by a bradykinin antagonist. Journal of Hypertension 6: S25–S28, 1988
Schunkert H, Kindler J, Gassmann M, Lahn W, Irmisch R, et al. Steady-state kinetics of ramipril in renal failure. Journal of Cardiovascular Pharmacology 13 (Suppl. 3): 52–54, 1989
Sharpe N, Murphy J, Smith H, Hannan S. Treatment of patients with symptomless left ventricular dysfunction after myocardial infarction. Lancet 1: 255–259, 1988
Shionoiri H, Gotoh E, Takagi N, Takeda K, Yabana M, et al. Antihypertensive effects and pharmacokinetics of single and consecutive doses of cilazapril in hypertensive patients with normal and impaired renal function. Journal of Cardiovascular Pharmacology 11: 242–249, 1988
Shionoiri H, Yasuda G, Abe Y, Yoshimura H, Kaneko Y, et al. Pharmacokinetics and acute effect on the renin-angiotensin system of delapril in patients with chronic renal failure. Clinical Nephrology 27: 65–70, 1987a
Shionoiri H, Yasuda G, Ikeda A, Ohta T, Miyajima E, et al. Pharmacokinetics and depressor effect of delapril in patients with essential hypertension. Clinical Pharmacology and Therapeutics 41: 74–79, 1987b
Singhvi SM, Duchin KL, Morrison A, Willard DA, Everett DW, et al. Disposition of fosinopril sodium in healthy subjects. British Journal of Clinical Pharmacology 25: 9–15, 1988
Singhvi SM, McKinstry DN, Shaw JM, Willard DA, Migdalof BH. Effect of food on the bioavailability of captopril in healthy subjects. Journal of Clinical Pharmacology 22: 135–140, 1982
Snedden W, Fernandez PG, Vasdev S, Bolli P. The 24-hour control of blood-pressure by chronic once-a-day cilazapril therapy. Abstract C-114. Clinical and Investigative Medicine 11 (Suppl. C18), 1988
Sugimoto K, Kumagai Y, Tateishi T, Seguchi H, Ebihara A. Effects on autonomic function of a new angiotensin converting enzyme inhibitor, ramipril. Journal of Cardiovascular Pharmacology 13 (Suppl. 3): S40–S45, 1989
Sybertz EJ, Baum T, Ahn HS, Desiderio DM, Pula KK, et al. Angiotensin converting enzyme inhibitory activity of SCH33844 (Spirapril) in rats, dogs and monkeys. Archives Internationales de Pharmacodynamie et de Thérapie 286: 216–229, 1987a
Sybertz EJ, Baum T, Ahn HS, Nelson S, Eynon E, et al. Angiotensin-converting enzyme inhibitory activity of SCH 31846, a new non-sulfhydryl inhibitor. Journal of Cardiovascular Pharmacology 5: 643–654, 1983
Sybertz EJ, Watkins RW, Ahn HS, Baum T, La Rocca P, et al. Pharmacologic, metabolic, and toxicologic profibrillationle of spirapril (SCH 33844), a new angiotensin converting inhibitor. Journal of Cardiovascular Pharmacology 10 (Suppl. 7): 105–108, 1987b
Takeyama K, Minato H, Fukuya F, et al. Antihypertensive activity of alacepril in spontaneously hypertensive rats and deoxycorticosterone acetate-salt hypertensive rats and dogs. Arzneimittel-Forschung 35: 1507–1512, 1985
Thuillez C, Richard C, Richer C, Loueslati H, Perret L, et al. Peripheral haemodynamic effects of perindopril compared in patients with congestive heart failure and in normal volunteers. Journal of Hypertension 6 (Suppl. 3): 41–43, 1988
Todd PA, Benfibrillationeld P. Ramipril: a review of its pharmacological properties and therapeutic efficacy in cardiovascular disorders. Drugs 39: 110–135, 1990
Todd PA, Heel RC. Enalapril: a review of its pharmacodynamie and pharmacokinetic properties, and therapeutic use in hypertension and congestive heart failure. Drugs 31: 198–248, 1986
Tsukiyama H, Otsuka K. Hemodynamic effects of new agents with vasodilating properties, celiprolol and larvedicol, and a new angiotensin converting enzyme inhibitor, altiopril, in essential hypertension. European Heart Journal 9 (Suppl. 1): 114, 1988
Unger T, Ganten D, Lang RE. Effect of converting enzyme inhibitors on tissue converting enzyme and angiotensin II: therapeutic imputations. American Journal of Cardiology 59: 18D–22D, 1988
Unger T, Ganten D, Lang RE, Scholkens B. Is tissue converting enzyme inhibition a determinant of the antihypertensive efficacy of converting enzyme inhibitor: studies with two different compounds, Hoe 492 and MK 421, in spontaneously hypertensive rats? Journal of Cardiovascular Pharmacology 6: 872–880, 1984
Unger T, Moursi M, Ganten D, Hermann K, Lang RE. Antihypertensive action of the converting enzyme inhibitor perindopril (S9490-3) in spontaneously hypertensive rats: comparison with enalapril (MK421) and ramipril (HOE498). Journal of Cardiovascular Pharmacology 8: 276–285, 1986
Valvo E, Casagrande P, Antigo L, Bedogna V, Alberti D, et al. Systemic and renal effects of a new ACE inhibitor, benazepril, in essential hypertension. Abstract F002. International Symposium on ACE inhibition, London, February 14–17, 1989
van Brummelen P, Kleinbloesem CH. The clinical pharmacology of cilazapril. Second International Symposium on Cilazapril: Clinical Aspects. Evolving Role of ACE Inhibitors in Cardiovascular Therapy, p. 24, Basle, February 9–11, 1989
van den Meiracker AH, Man in’t Veld AJ, Admiraal P, Boomsma F, Schalekamp MADH. Acute versus chronic ACE-inhibition in relation to duration of antihypertensive effect; experience with spirapril, a new ACE-inhibitor. Abstract F040. International Symposium on ACE Inhibition, London, February 14–17, 1989
Van Gilst WH, Scholtens E, De Graef PA, et al. Differential influences of angiotensin converting enzyme inhibitors on the coronary circulation. Circulation 77 (Suppl. I): I24–I29, 1988
Vidt DG, Bravo EL, Fouad FM. Captopril. New England Journal of Medicine 306: 214–219, 1982
Waeber B, Aubert JF, Vavrek R, Stewart JM, Nussberger J, et al. Role of bradykinin in blood pressure regulation of conscious spontaneously hypertensive rats. Journal of Hypertension 4 (Suppl. 6): 597–598, 1986
Waeber B, Brunner HR, Brunner DR, Curtet AL, Turini G, et al. Discrepancy between antihypertensive effect and angiotensin converting enzyme inhibition by captopril. Hypertension 2: 236–242, 1980
Waeber G, Fasanella d’Amore T, Nussberger J, Waeber B, et al. Effect on blood pressure and the renin-angiotensin system of repeated doses of the converting enzyme inhibitor CGS 14824A. European Journal of Clinical Pharmacology 31: 643–646, 1987
Watkins RW, Sybertz EJ, Antonellis A, Pula K. Effects of spirapril acid, an angiotensin converting enzyme inhibitor, on large artery compliance in anesthetized dogs. Archives Internationales de Pharmacodynamie et de Thérapie 290: 222–234, 1987
Webb DJ, Collier JG, Seidelinm PH, Struthers AD. Regulation of regional vascular tone: the role of angiotensin conversion in human forearm resistance vessels. Journal of Hypertension 6 (Suppl. 3): 57–59, 1988
Weber MA, Ferraresi RW, Poorvin D. Evaluation of a new angiotensin converting enzyme inhibitor, spirapril, in mild to moderate essential hypertension. Journal of Hypertension 4 (Suppl. 6): 171–173, 1986
Wenting GJ, Blankestijn PJ, Poldermans D, et al. Blood pressure response to nephrectomized subjects and patients with essential hypertension to ramipril: indirect evidence that inhibition of tissue angiotensin converting enzyme is important. American Journal of Cardiology 59: 92D–97D, 1987
Westlin W, Mullane K. Does captopril attenuate reperfusion-induced myocardial dysfunction by scavenging free radicals? Circulation 77 (Suppl. I): 130–139, 1988
White WB, McCabe EJ, Hager D, Schulman P. The effects of the long-acting angiotensin converting enzyme inhibitor cilazapril on casual, exercise, and ambulatory blood pressure. Clinical Pharmacology and Therapeutics 44: 173–178, 1988
Williams GH. Converting enzyme inhibitors in the treatment of hypertension. New England Journal of Medicine 319: 1517–1525, 1988
Williams PEO, Brown AN, Rajaguru S, Walters GE, McEwen J, et al. A pharmacokinetic study of cilazapril in elderly and young volunteers. First International Symposium on Cilazapril: Preclinical and Clinical Pharmacology, p. 14, Lausanne, May 5–7, 1988
Wills RJ, Massarella JW, Silvestri TM, Brown AN, Lin A. The influence of food on the pharmacokinetics and ACE inhibition of cilazapril. First International Symposium on Cilazapril: Preclinical and Clinical Pharmacology, p. 13, Lausanne, May 5–7, 1988
Witte PU, Irmisch R, Hajdù P, Metzger H. Pharmacokinetics and pharmacodynamics of a novel orally active angiotensin converting enzyme inhibitor (HOE 498) in healthy subjects. European Journal of Clinical Pharmacology 27: 577–581, 1984
Witte PU, Walter U. Comparative double-blind study of ramipril and captopril in mild to moderate essential hypertension. American Journal of Cardiology 59: 115D–120D, 1987
Xiang JZ, Linz W, Becker H, Ganten D, Lang RE. Effects of converting enzyme inhibitors: ramipril and enalapril on peptide action and sympathetic neurotransmission in the isolated heart. European Journal of Pharmacology 113: 215–223, 1985
Yoshida K, Tsukamoto T, Kobayashi T, et al. Pharmacokinetics and metabolism of alindapril hydrochloride (CV-3317), a new angiotensin converting enzyme inhibitor, in rats and dogs. Japanese Journal of Pharmacology and Therapy 13: 163–177, 1985
Zabludowski J, Rosenfeld J, Akbary MA, Schinzel S. A multicenter, randomized, double blind study comparing the antihypertensive efficacy and safety of ramipril with enalapril in mild to moderate hypertension. European Heart Journal 9 (Suppl. 1): 76, 1988
Zanchetti A. Perindopril: first line treatment in hypertension. 1st International Meeting on Hypertension, Renin-Angiotensin System and Perindopril (Coversyl), Paris, October 29, 1988
Zusman R. Effects of converting enzyme inhibitors on the reninangiotensin-aldosterone, bradykinin, and arachidonic acid-prostaglandin systems: correlation of chemical structure and biologic activity. American Journal of Kidney Diseases 10 (Suppl. 1): 13–23, 1987
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Salvetti, A. Newer ACE Inhibitors. Drugs 40, 800–828 (1990). https://doi.org/10.2165/00003495-199040060-00004
Published:
Issue Date:
DOI: https://doi.org/10.2165/00003495-199040060-00004